Wang Zhenghua, Yan Zhihong, Yan Shengyong, Li Jin, Wang Qingbin, Yu Xuefeng, Wang Haomeng, Zhao Xuan, Zhu Tao
Cansino (Shanghai) Biological Research Co. Ltd., Buildings 7, No. 67, Libing Road, Pudong District, Shanghai 201210, P. R. China.
JenKem Technology Inc., No. 9 Kangcheng Street, West Zone of TEDA Development Zone, Tianjin 300462, P. R. China.
ACS Appl Mater Interfaces. 2025 Jun 25;17(25):36377-36386. doi: 10.1021/acsami.5c04597. Epub 2025 Jun 12.
Lipid nanoparticles (LNPs) have shown great promise for nucleic acid drug delivery. Canonical LNPs consist of four lipid components: ionizable lipid, cholesterol, Polyethylene glycol-yl-lipid (PEGyl-lipid), and phospholipid. However, these traditional LNPs face limitations in mRNA vaccine delivery, including liver-targeted transfection and the insufficient activation of cellular immune responses. A more efficacious and safer LNP system remains a great challenge. Herein, we report ionizable sterol lipid-based three-component LNPs (ISL-3C-LNPs), which exhibit high mRNA encapsulation and delivery efficiency. Among these, CS22021-based ISL-3C-LNP demonstrated localized mRNA delivery at the injection site following intramuscular administration, which potentially contributes to a good safety profile. Moreover, the CS22021-based ISL-3C-LNP enabled the efficient delivery of a varicella-zoster virus (VZV) mRNA vaccine by eliciting robust humoral and cellular immune responses. Notably, it elicited a significantly higher CD8T cell response compared to a conventional LNP formulation, highlighting its potential in mRNA vaccine applications requiring enhanced CD8T cell activation, such as mRNA cancer vaccines.
脂质纳米颗粒(LNPs)在核酸药物递送方面显示出巨大的潜力。典型的LNPs由四种脂质成分组成:可电离脂质、胆固醇、聚乙二醇脂质(PEGyl-脂质)和磷脂。然而,这些传统的LNPs在mRNA疫苗递送方面面临局限性,包括肝脏靶向转染和细胞免疫反应激活不足。开发一种更有效、更安全的LNP系统仍然是一个巨大的挑战。在此,我们报道了基于可电离甾醇脂质的三组分LNPs(ISL-3C-LNPs),其表现出高mRNA包封率和递送效率。其中,基于CS22021的ISL-3C-LNP在肌肉注射后在注射部位实现了局部mRNA递送,这可能有助于良好的安全性。此外,基于CS22021的ISL-3C-LNP通过引发强烈的体液和细胞免疫反应,实现了水痘带状疱疹病毒(VZV)mRNA疫苗的有效递送。值得注意的是,与传统的LNP制剂相比,它引发了显著更高的CD8T细胞反应,突出了其在需要增强CD8T细胞激活的mRNA疫苗应用中的潜力,如mRNA癌症疫苗。